hD16F7

hD16F7 is a humanized monoclonal antibody (mAb) that targets vascular endothelial growth factor receptor-1 (VEGFR-1), a tyrosine kinase receptor involved in angiogenesis, tumor invasiveness, and the recruitment of pro-tumoral M2 macrophages. A distinguishing feature of hD16F7 is its ability to inhibit the signaling of membrane-bound VEGFR-1 while preserving the decoy function of soluble VEGFR-1 (sVEGFR-1), which naturally sequesters VEGF-A and placental growth factor (PlGF) in the tumor microenvironment. In preclinical studies, hD16F7 has demonstrated the ability to inhibit PlGF-induced migration of melanoma, glioblastoma, and endothelial cells. It has also shown efficacy in patient-derived tumor xenografts (PDTXs) of melanoma, both as a monotherapy and in combination with BRAF inhibitors like vemurafenib. Furthermore, hD16F7 serves as the targeting component for antibody-drug conjugates (ADCs) utilizing payloads such as monomethyl auristatin E (MMAE) and pyrrolobenzodiazepine (PBD) to deliver cytotoxic effects directly to VEGFR-1-expressing tumor and microenvironment cells.

Other names

humanized anti-VEGFR-1 monoclonal antibody hD16F7